Notice on Updates to Plans and Growth Potential

Section Heading

This update communicates updates to development pipeline progress plans and status of clinical trial applications and approvals, focusing on the glaucoma treatment product centered on H-1337 and other development products. Development schedule includes updates to the start timing of Phase 3, with favorable results in Phase 2b, and a policy prioritizing development in Japan. Regional development products are described for Japan, the United States, China, etc., with expectations for future submissions and approvals. Overall, this update includes development plans with license-out considerations, and provides reference for development risks and progress charts.

Section 2 Heading

For shareholders and investors, progress of the development pipeline and the schedule for clinical trial approval submissions are important information. The update indicates small-dose confirmation trials starting in 2029, and the future progress of clinical trials and the overall pipeline roadmap are expected to be of high importance. This document describes regional progress, assumptions of development plans, and policy for disclosure as soon as confirmations are made, providing materials for evaluating development risk and opportunities in investment decisions.